Imaging technology to improve diagnostic of Parkinsonism
Parkinsonism is the second most prevalent neurodegenerative disorder after Parkinson’s disease (PD), and 20 % of patients are diagnosed with atypical parkinsonisms (AP). AP tends to be therapy-resistant and presents a faster degeneration rate than PD. The EU-funded SYNPARK project is an interdisciplinary action that will investigate the value of the different imaging markers' modalities in various parkinsonism forms. Improving diagnostic accuracy is important now, when disease-modifying therapies are becoming available for PD. The research involves a multidisciplinary approach of the in vivo synaptic molecular brain assessment using positron emission tomography (PET), the whole-brain connectomics organisation using magnetic resonance imaging and the clinical validation of a new generation PET tracer in AP/PD.
Fields of science
- medical and health sciencesbasic medicinephysiologypathophysiology
- social sciencespolitical sciencespolitical transitionsrevolutions
- engineering and technologymedical engineeringdiagnostic imagingmagnetic resonance imaging
- medical and health sciencesbasic medicineneurologyparkinson
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Funding SchemeMSCA-IF-GF - Global Fellowships
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
M6J 1H4 Toronto
See on map